Cancer has no borders. Neither do we.

We transcend borders, time zones, and especially the status quo to develop therapies that are more accessible to people around the world.

Learn More

We transcend borders, time zones, and especially the status quo to develop therapies that are more accessible to people around the world.

Learn More

Putting Patients First

We offer resources to help patients and their loved ones navigate some of the complex challenges that follow the words, “You have cancer.”

Learn More
elder_women

Science-Based, Passion-Driven

We are advancing an innovative, high-value product portfolio for patients globally.

Learn More
doctor_and_patient

Passion with Purpose

We work to benefit patients wherever they live by uniting worldwide talent and resources with our vision.

Learn More
people_walking

BeiGene News

January 19, 2023

BRUKINSA® Approved in the U.S. for Chronic Lymphocytic Leukemia

Read more

January 19, 2023

BRUKINSA® (zanubrutinib) Receives Marketing Authorization for Chronic Lymphocytic Leukemia (CLL) and Marginal Zone Lymphoma (MZL) in Great Britain by MHRA

Read more

January 18, 2023

BeiGene Announces Expansion of Coverage on China’s National Reimbursement Drug List

Read more

January 17, 2023

BeiGene Presents New Research from Tislelizumab Global Development Program at 2023 ASCO Gastrointestinal Cancers Symposium

Read more

January 4, 2023

BeiGene to Present at the J.P. Morgan 41st Annual Healthcare Conference

Read more

December 30, 2022

BeiGene Announces Acceptance of 12th Regulatory Submission in China for PD-1 Inhibitor Tislelizumab

Read more